Molecular Pathology of Hematologic Malignancies

1. Zhang N, Wu J, Wang Q et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023; 13(1): 82. Zhang N Wu J Wang Q . Global burden of hematologic malignancies and evolution patterns over the past 30 years . Blood Cancer J . 2023 ; 13 ( 1 ): 82 . Search in Google Scholar

2. Rao D, Said J. Pathology and Molecular Pathology of Hematologic Malignancies Rao D Said J. Pathology and Molecular Pathology of Hematologic Malignancies Search in Google Scholar

3. Beck RC, Kim AS, Goswami RS et al. A Recommended Curriculum From The Society for Hematopathology and the Association for Molecular Pathology. Am J Clin Pathol 2020;154:149–177 Beck RC Kim AS Goswami RS . A Recommended Curriculum From The Society for Hematopathology and the Association for Molecular Pathology . Am J Clin Pathol 2020 ; 154 : 149 – 177 Search in Google Scholar

4. Mukkamalla SKR, Taneja A, Malipeddi D et al. Chronic Lymphocytic Leukemia. StatPearls Publishing; 2024 Jan-. Mukkamalla SKR Taneja A Malipeddi D . Chronic Lymphocytic Leukemia . StatPearls Publishing ; 2024 Jan -. Search in Google Scholar

5. Wainman LM, Khan WA, Kaur P. Chronic Lymphocytic Leukemia: Current Knowledge and Future Advances in Cytogenomic Testing. In: Sergi CM, editor. Advancements in Cancer Research. Brisbane (AU): Exon Publications; Online first 08 Feb 2023. p. 93–106 Wainman LM Khan WA Kaur P. Chronic Lymphocytic Leukemia: Current Knowledge and Future Advances in Cytogenomic Testing . In: Sergi CM , editor. Advancements in Cancer Research . Brisbane (AU) : Exon Publications ; Online first 08 Feb 2023. p. 93 – 106 Search in Google Scholar

6. Goy J, Gillan TL, Bruyere H et al. Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada. Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 6, 2017, p. 382–389. Goy J Gillan TL Bruyere H . Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada . Clinical Lymphoma Myeloma and Leukemia , Volume 17 , Issue 6 , 2017 , p. 382 – 389 . Search in Google Scholar

7. Dave SS, Fu K, Wright GW et al. Molecular Diagnosis of Burkitt’s Lymphoma. N Engl J Med 2006; 354:2431–2442 Dave SS Fu K Wright GW . Molecular Diagnosis of Burkitt’s Lymphoma . N Engl J Med 2006 ; 354 : 2431 – 2442 Search in Google Scholar

8. Burkhardt, B, Michgehl, U, Rohde, J. et al. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat Commun 13, 3881 (2022). Burkhardt B Michgehl U Rohde J. . Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age . Nat Commun 13 , 3881 ( 2022 ). Search in Google Scholar

9. Roschewski M, Phelan JD, Wilson WH. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. Cancer J. 2020 May/Jun;26(3):195–205. Roschewski M Phelan JD Wilson WH. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma . Cancer J . 2020 May/Jun ; 26 ( 3 ): 195 – 205 . Search in Google Scholar

10. Navarro A, Beà S, Jares P et al. Molecular Pathogenesis of Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020 Oct;34(5):795–807 Navarro A Beà S Jares P . Molecular Pathogenesis of Mantle Cell Lymphoma . Hematol Oncol Clin North Am . 2020 Oct ; 34 ( 5 ): 795 – 807 Search in Google Scholar

11. Jain P, Wang ML. Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach,and current and novel treatments. Am J Hematol.2022;97:638–656. Jain P Wang ML. Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach,and current and novel treatments . Am J Hematol . 2022 ; 97 : 638 – 656 . Search in Google Scholar

12. López C, Mozas P, López-Guillermo A et al. Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice. Hemato 2022, 3(4), 595–614. López C Mozas P López-Guillermo A . Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice . Hemato 2022 , 3 ( 4 ), 595 – 614 . Search in Google Scholar

13. Bohn JP, Salcher S, Pircher A et al. The Biology of Classic Hairy Cell Leukemia. Int. J. Mol. Sci. 2021, 22(15), 7780 Bohn JP Salcher S Pircher A . The Biology of Classic Hairy Cell Leukemia . Int. J. Mol. Sci . 2021 , 22 ( 15 ), 7780 Search in Google Scholar

14. Durham BH, Getta B, Dietrich S et al. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017 Oct 5; 130(14): 1644–1648. Durham BH Getta B Dietrich S . Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations . Blood . 2017 Oct 5 ; 130 ( 14 ): 1644 – 1648 . Search in Google Scholar

15. Rodríguez-Sevilla JJ, Salar A. Recent Advances in the Genetic of MALT Lymphomas. Cancers 2022, 14(1), 176 Rodríguez-Sevilla JJ Salar A. Recent Advances in the Genetic of MALT Lymphomas . Cancers 2022 , 14 ( 1 ), 176 Search in Google Scholar

16. Heider M, Nickel K, Högner M et al. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncol Res Treat (2021) 44 (12): 672–681. Heider M Nickel K Högner M . Multiple Myeloma: Molecular Pathogenesis and Disease Evolution . Oncol Res Treat ( 2021 ) 44 ( 12 ): 672 – 681 . Search in Google Scholar

17. Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells 2021, 10(2), 336 Cardona-Benavides IJ de Ramón C Gutiérrez NC. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications . Cells 2021 , 10 ( 2 ), 336 Search in Google Scholar

18. Foucar K, Bagg A, Bueso-Ramos CE et al. Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach, American Journal of Clinical Pathology, Volume 160, Issue 4, October 2023, Pages 365–393. Foucar K Bagg A Bueso-Ramos CE . Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach, American Journal of Clinical Pathology , Volume 160 , Issue 4 , October 2023 , Pages 365 – 393 . Search in Google Scholar

19. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood (2017) 129 (6): 667–679. Vainchenker W Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms . Blood ( 2017 ) 129 ( 6 ): 667 – 679 . Search in Google Scholar

20. Alshemmari SH, Rajan R, Emadi A. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review. Med Princ Pract (2016) 25 (6): 501–509. Alshemmari SH Rajan R Emadi A. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review . Med Princ Pract ( 2016 ) 25 ( 6 ): 501 – 509 . Search in Google Scholar

21. Sara Benchikh S, Bousfiha A, Hamouchi AE et al. Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution. Egypt J Med Hum Genet 23, 29 (2022). Sara Benchikh S Bousfiha A Hamouchi AE . Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution . Egypt J Med Hum Genet 23 , 29 ( 2022 ). Search in Google Scholar

22. Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica 2017 Volume 102(1):7–17. Grinfeld J Nangalia J Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms . Haematologica 2017 Volume 102 ( 1 ): 7 – 17 . Search in Google Scholar

23. Prins D,1 Arias CG,1 Klampfl T. Mutant Calreticulin in the Myeloproliferative Neoplasms. Hemasphere. 2020 Feb; 4(1): e333. Prins D 1 Arias CG 1 Klampfl T. Mutant Calreticulin in the Myeloproliferative Neoplasms . Hemasphere . 2020 Feb ; 4 ( 1 ) : e333. Search in Google Scholar

24. Haferlach T. The Molecular Pathology of Myelodysplastic Syndrome. Pathobiology (2019) 86 (1): 24–29. Haferlach T. The Molecular Pathology of Myelodysplastic Syndrome . Pathobiology ( 2019 ) 86 ( 1 ): 24 – 29 . Search in Google Scholar

25. Lee P, Yim R, Yung Y, Chu H-T, Yip P-K, Gill H. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome. International Journal of Molecular Sciences. 2021; 22(19):10232. Lee P Yim R Yung Y Chu H-T Yip P-K Gill H. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome . International Journal of Molecular Sciences . 2021 ; 22 ( 19 ): 10232 . Search in Google Scholar

26. Demir D. Insights into the new molecular updates in acute myeloid leukemia pathogenesis. Genes 2023,14,1424. Demir D. Insights into the new molecular updates in acute myeloid leukemia pathogenesis . Genes 2023 , 14 , 1424 . Search in Google Scholar

27. Khoury JD, Solary E, Abla O et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7): 1703–1719. Khoury JD Solary E Abla O . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms . Leukemia . 2022 ; 36 ( 7 ): 1703 – 1719 . Search in Google Scholar

28. Döhner H, Wei AH, Appelbaum FR et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140: 1345–1377. Döhner H Wei AH Appelbaum FR . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN . Blood . 2022 ; 140 : 1345 – 1377 . Search in Google Scholar

29. Graham BS, Lynch DT. Burkitt Lymphoma. [Updated 2023 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538148/ Graham BS Lynch DT. Burkitt Lymphoma . [ Updated 2023 Aug 7 ]. In: StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing ; 2024 Jan -. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538148/ Search in Google Scholar

30. Kim S, Kim H, Kang H et al. Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. J Hematol Oncol. 2013 Oct 3;6:76. Kim S Kim H Kang H . Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement . J Hematol Oncol . 2013 Oct 3 ; 6 : 76 . Search in Google Scholar

31. Sehn LH, Fenske TS, Laport GG. Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 18:S82–S91, 2012 Sehn LH Fenske TS Laport GG. Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation . Biol Blood Marrow Transplant 18 :S82–S91, 2012 Search in Google Scholar